Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«JAK2

Below is an extended JAK2 news listing. Click here to return to the gene page.

BioNews Results for JAK2:
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient PR Newswire: Oct 28 2009 12:23PM Matching: jak2
Residents turn to researchers hoping to find cause of cancer cluster TradingMarkets: Oct 25 2009 7:48PM Matching: jak2
Residents turn to researchers hoping to find cause of cancer cluster Standard Speaker: Oct 25 2009 2:37PM Matching: jak2
Cancer cluster residents learn government's plans for study Citizens Voice: Oct 25 2009 8:32AM Matching: jak2
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient Pharma Live: Oct 25 2009 1:47AM Matching: jak2
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient KOTA Territory News: Oct 23 2009 11:57AM Matching: jak2
TargeGen, Inc. Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis P BioSpace: Oct 23 2009 5:52PM Matching: jak2
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients SmartBrief: Oct 22 2009 11:50PM Matching: jak2
Medical News: TargeGen Announces Successful Completion Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myelofibrosis Patients Medical News Today: Oct 23 2009 1:12PM Matching: jak2
TargeGen Announces Successful Completion Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myelofibrosis Patient Medical News Today: Oct 23 2009 9:55AM Matching: jak2
First Myelofibrosis Treatment Trial Ends Pharmaceutical Technology: Oct 23 2009 10:31AM Matching: jak2
TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients News-Medical.Net: Oct 23 2009 4:51AM Matching: jak2
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival Leukemia: Oct 22 2009 2:37PM Matching: jak2
TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patient Genetic Engineering News: Oct 22 2009 9:12PM Matching: jak2
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational statusclinical correlates in a study of 226 consecutive patients Leukemia: Oct 22 2009 2:37PM Matching: jak2

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.